Soupart A, Penninckx R, Stenuit A, Decaux G
Research Unit for the Study of Hydromineral Metabolism, Erasmus University Hospital, Free University of Brussels, Belgium.
Brain Res. 2000 Jan 3;852(1):167-72. doi: 10.1016/s0006-8993(99)02259-3.
Brain myelinolysis complicates excessive correction of chronic hyponatremia in man. Myelinolysis appear in rats for correction levels deltaSNa) > 20 mEq/l/24 h. We previously showed in rats that when chronic hyponatremia was corrected with urea, the incidence and the severity of brain lesions were significantly reduced compared to hypertonic saline. In man, hyponatremia is frequently associated with azotemia and hemo-dialysis usually corrects rapidly the serum sodium (SNa) but only few patients apparently develop demyelination. We hypothesize that uremic state protects brain against myelinolysis. This hypothesis was evaluated in rats developing azotemia by administration of mercuric chloride (HgCl2, 1.5 mg/kg). Severe (SNa < 120 mEq/l) hyponatremia (3 days) was induced by S.C. AVP and i.p. 2.5% D-glucose for 3 days. HgCl2 was injected on day 2. Hyponatremia was corrected on day 4 by i.p. injections of 5% NaCl in order to obtain a correction level largely above the toxic threshold for brain (deltaSNA approximately 30 mEq/l/24 h). Surviving rats were decapitated on day 10 for brain analysis. In the group with renal failure (Group I, n = 15, urea 59 mmol/l) the outcome was remarkably favourable with only three rats (3/15) dying before day 10 and only one of them (1/3) presenting myelinolysis-related neurologic symptoms. The 12 other rats (80%) survived in Group I without symptoms and brain analysis was normal in all of them despite large correction level (deltaSNa: 32 mEq/l/24 h). On the contrary in nine rats in which HgCl, did not produce significant azotemia (control 1, n = 9, urea: 11 mmol/l), all the rats developed severe neurologic symptoms and eight of them died before day 10. Similar catastrophic outcome was observed in the non-azotemic controls (control 2, no HgCl2 administration, n = 15, urea: 5 mmol/l). All of them developed myelinolysis-related neurologic symptoms and only four of them survived with severe brain lesions (survival 12/15 in Group I vs. 5/24 in pooled controls 1 and 2, p < 0.001). In conclusion, we showed for the first time that chronic hyponatremic rats with azotemia (48 h) tolerated large increases in SNa (approximately 30 mEq/l/24 h) without significant brain damage.
脑髓鞘溶解症是人类慢性低钠血症过度纠正后的并发症。当大鼠的血钠纠正水平(deltaSNa)>20 mEq/l/24 h时会出现髓鞘溶解症。我们之前在大鼠中发现,与高渗盐水相比,用尿素纠正慢性低钠血症时,脑损伤的发生率和严重程度显著降低。在人类中,低钠血症常与氮质血症相关,血液透析通常能迅速纠正血清钠(SNa),但只有少数患者明显发生脱髓鞘。我们推测尿毒症状态可保护大脑免受髓鞘溶解症的影响。通过给予氯化汞(HgCl2,1.5 mg/kg)使大鼠发生氮质血症,对这一推测进行了评估。通过皮下注射抗利尿激素(AVP)和腹腔注射2.5% D -葡萄糖3天诱导出严重(SNa < 120 mEq/l)低钠血症(持续3天)。在第2天注射HgCl2。在第4天通过腹腔注射5% NaCl纠正低钠血症,以使纠正水平大大高于大脑的毒性阈值(deltaSNA约为30 mEq/l/24 h)。存活的大鼠在第10天断头进行脑分析。在肾衰竭组(I组,n = 15,尿素59 mmol/l),结果非常有利,只有3只大鼠(3/15)在第10天前死亡,其中只有1只(1/3)出现与髓鞘溶解症相关的神经症状。I组的另外12只大鼠(80%)无症状存活,尽管纠正水平较高(deltaSNa:32 mEq/l/24 h),但它们的脑分析均正常。相反,在9只HgCl2未产生明显氮质血症的大鼠(对照1组,n = 9,尿素:11 mmol/l)中,所有大鼠都出现了严重的神经症状,其中8只在第10天前死亡。在非氮质血症对照组(对照2组,未给予HgCl2,n = 15,尿素:5 mmol/l)也观察到了类似的灾难性结果。它们都出现了与髓鞘溶解症相关的神经症状,只有4只存活且有严重的脑损伤(I组存活率为12/15;合并对照组1和2为5/24,p < 0.001)。总之,我们首次表明,患有氮质血症(48小时)的慢性低钠血症大鼠能够耐受SNa的大幅升高(约30 mEq/l/24 h)而无明显脑损伤。